Body Composition Changes on DRV/r + either RAL or TDF/FTC As First-Line ART
Data on body composition, adipokines and inflammatory markers changes after initial therapy with a nucleos(t)ide reverse transcriptase inhibitor (NtRTI)- sparing or containing regimen are scarce. The effect of tenofovir/emtricitabine (TDF/FTC) vs raltegarvir (RAL), both in association with ritonavir-boosted darunavir (DRV/r) could be relevant for treatment choice. NEAT001/ANRS143 is a randomised 1:1, open-label, non-inferiority trial comparing…